Postoperative radiotherapy in salivary ductal carcinoma: a single institution experience

  • Kim, Tae Hyung (Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine) ;
  • Kim, Mi Sun (Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine) ;
  • Choi, Seo Hee (Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine) ;
  • Suh, Yang Gun (Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine) ;
  • Koh, Yoon Woo (Department of Otorhinolaryngology, Yonsei University College of Medicine) ;
  • Kim, Se Hun (Department of Otorhinolaryngology, Yonsei University College of Medicine) ;
  • Choi, Eun Chang (Department of Otorhinolaryngology, Yonsei University College of Medicine) ;
  • Keum, Ki Chang (Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine)
  • Received : 2014.04.22
  • Accepted : 2014.06.23
  • Published : 2014.09.30


Purpose: We reviewed treatment outcomes and prognostic factors for patients with salivary ductal carcinoma (SDC) treated with surgery and postoperative radiotherapy from 2005 to 2012. Materials and Methods: A total of 16 patients were identified and 15 eligible patients were included in analysis. Median age was 61 years (range, 40 to 71 years) and 12 patients (80%) were men. Twelve patients (80%) had a tumor in the parotid gland, 9 (60%) had T3 or T4 disease, and 9 (60%) had positive nodal disease. All patients underwent surgery and postoperative radiotherapy. Postoperative radiotherapy was delivered using 3-dimensional conformal radiotherapy or intensity-modulated radiotherapy. Locoregional failure-free survival (LRFFS), distant failure-free survival (DFFS), progression-free survival (PFS), and overall survival (OS) were calculated using the Kaplan-Meier method. Differences in survival based on risk factors were tested using a log-rank test. Results: Median total radiotherapy dose was 60 Gy (range, 52.5 to 63.6 Gy). Four patients received concurrent weekly chemotherapy with cisplatin. Among 10 patients who underwent surgery with neck dissection, 7 received modified radical neck dissection. With a median follow-up time of 38 months (range, 24 to 105 months), 4-year rates were 86% for LRFFS, 51% for DFFS, 46% for PFS, and 93% for OS. Local failure was observed in 2 patients (13%), and distant failure was observed in 7 (47%). The lung was the most common involved site of distant metastasis. Conclusion: Surgery and postoperative radiotherapy in SDC patients resulted in good local control, but high distant metastasis remained a major challenge.


  1. Lewis JE, McKinney BC, Weiland LH, Ferreiro JA, Olsen KD. Salivary duct carcinoma. Clinicopathologic and immunohistochemical review of 26 cases. Cancer 1996;77:223-30.<223::AID-CNCR1>3.0.CO;2-N
  2. Perissinotti AJ, Lee Pierce M, Pace MB, El-Naggar A, Kies MS, Kupferman M. The role of trastuzumab in the management of salivary ductal carcinomas. Anticancer Res 2013;33:2587-91.
  3. Hosal AS, Fan C, Barnes L, Myers EN. Salivary duct carcinoma. Otolaryngol Head Neck Surg 2003;129:720-5.
  4. Jaehne M, Roeser K, Jaekel T, Schepers JD, Albert N, Loning T. Clinical and immunohistologic typing of salivary duct carcinoma: a report of 50 cases. Cancer 2005;103:2526-33.
  5. Haddad R, Colevas AD, Krane JF, et al. Herceptin in patients with advanced or metastatic salivary gland carcinomas: a phase II study. Oral Oncol 2003;39:724-7.
  6. Kim H, Kim H, Kim H, Kim J, Hong SW, Kim SH. Salivary duct carcinoma with mucin containing cells: report of a case misdiagnosed as mucoepidermoid carcinoma on fine needle aspiration cytology. Korean J Cytopathol 2006;17:56-62.
  7. Moon SH, Yoo G, Choi YS, Lim JS, Han KT. Treatment of salivary duct carcinoma: a case report. J Korean Cleft Palate-Craniofac Assoc 2008;9:23-6.
  8. Park SH, Yoo DH, Kim KH, Koh ES. A case of salivary duct carcinoma in parotid gland. Korean J Otolaryngol-Head Neck Surg 1997;40:695-8.
  9. Park SW, Kang SY, Kim TH, Kim CH. A case report of salivary duct carcinoma. J Korean Soc Plast Reconstr Surg 2008;35:607-10.
  10. Kim JY, Lee S, Cho KJ, et al. Treatment results of post-operative radiotherapy in patients with salivary duct carcinoma of the major salivary glands. Br J Radiol 2012;85:e947-52.
  11. Barnes L, Rao U, Krause J, Contis L, Schwartz A, Scalamogna P. Salivary duct carcinoma. Part I. A clinicopathologic evaluation and DNA image analysis of 13 cases with review of the literature. Oral Surg Oral Med Oral Pathol 1994;78:64-73.
  12. Brandwein MS, Jagirdar J, Patil J, Biller H, Kaneko M. Salivary duct carcinoma (cribriform salivary carcinoma of excretory ducts): a clinicopathologic and immunohistochemical study of 12 cases. Cancer 1990;65:2307-14.<2307::AID-CNCR2820651024>3.0.CO;2-1
  13. Guzzo M, Di Palma S, Grandi C, Molinari R. Salivary duct carcinoma: clinical characteristics and treatment strategies. Head Neck 1997;19:126-33.<126::AID-HED7>3.0.CO;2-6
  14. Williams MD, Roberts D, Blumenschein GR Jr, et al. Differential expression of hormonal and growth factor receptors in salivary duct carcinomas: biologic significance and potential role in therapeutic stratification of patients. Am J Surg Pathol 2007;31:1645-52.
  15. Nabili V, Tan JW, Bhuta S, Sercarz JA, Head CS. Salivary duct carcinoma: a clinical and histologic review with implications for trastuzumab therapy. Head Neck 2007;29:907-12.
  16. Shinoto M, Shioyama Y, Nakamura K, et al. Postoperative radiotherapy in patients with salivary duct carcinoma: clinical outcomes and prognostic factors. J Radiat Res 2013;54:925-30.